Ginkgo Bioworks Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Reuters
07-30
<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Ginkgo Bioworks Holdings Inc., a leader in cell programming and biosecurity, has been awarded a $4.66 million contract to deliver an advanced automated anaerobic phenotyping platform to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. This system, based on Ginkgo's Reconfigurable Automation Cart $(RAC)$ technology, will consist of an integrated workcell with 18 devices housed within a modular anaerobic chamber. The platform will enable EMSL scientists to conduct complex end-to-end anaerobic phenotyping workflows remotely, enhancing research efficiency and accelerating discoveries in microbial engineering and bioeconomy science. This collaboration aims to strengthen U.S. leadership in biotechnology and bioeconomy research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE40506) on July 30, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10